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Treatment of pulmonary artery stump thrombosis after lobectomy: 
a case report and literature review
Abstract
Introduction: Lung cancer surgery is a well-known risk factor for venous thromboembolism. Thus, standard care involves the use 
of pharmacological and mechanical prophylaxis until discharge from the hospital. Pulmonary artery stump thrombosis (PAST) is a 
rare condition which can develop months to years after lung cancer surgery. This report describes a patient diagnosed with PAST 
and the decisions that were made regarding his treatment. 
Case report: A 67-year-old male was diagnosed with lung cancer due to shortness of breath, dry cough, hemoptysis, and typical 
chest computed tomography (CT) findings. He underwent right lower lobectomy and mediastinal lymphadenectomy by video-as-
sisted thoracoscopic surgery. The procedure was complicated by the development of a right pleural empyema. After pleural 
drainage and an antibiotic regimen, he was discharged from the hospital with further improvement.
A follow-up CT pulmonary angiography performed three months after lobectomy revealed thrombosis in the right lower lobar 
pulmonary artery stump. The patient had no symptoms. 
The attending physician decided to use anticoagulants. Consequently, the patient received low-molecular-weight heparin subcu-
taneously for one month and a non-vitamin-K antagonist oral anticoagulant (NOAC) for the following 5 months. 
A CT scan performed after 3 months of anticoagulation showed complete resolution of stump thrombosis. Subsequent examina-
tions showed no recurrence of either lung cancer or artery stump thrombosis and no anticoagulant-related bleeding. 
Discussion: Pulmonary artery stump thrombosis can develop after lung cancer surgery. This complication is uncommon and the 
prognosis is favorable in most treated cases. However, thrombosis may progress, and pulmonary embolism or chronic thrombo-
embolic pulmonary hypertension may develop. Decisions about instituting anticoagulation therapy and its duration are made on 
an individual basis after considering both the benefits and the potential risks. 
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Introduction
The risk of developing venous thromboembo-
lism (VTE), including pulmonary embolism (PE) 
and/or deep vein thrombosis, after lung cancer 
surgery is approximately 2% (0.2–19%) [1], with 
the highest incidence within the first months after 
surgery [2]. Most VTE cases are asymptomatic at 
diagnosis but despite prophylaxis and treatment, 
the 30-day mortality rate is around 5% [3]. The 
prevalence of pulmonary artery stump thrombo-
sis (PAST) after all types of lung cancer surgery 
collectively in retrospective analyses ranged from 
1.9–5.7% [4, 5]. The clinical significance of PAST 
is unclear. The disease can be mild or it can be 
fatal. Moreover, there is no consensus about the 
use of anticoagulation therapy in such cases. 
Case report
A 67-year-old male lung cancer patient was 
admitted to the hospital in January 2017. He re-
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ported shortness of breath, dry cough, and one 
episode of hemoptysis. The patient had a history 
of bronchiectasis, emphysema, arterial hyper-
tension, heart failure with preserved ejection 
fraction, impaired fasting glucose, and abdominal 
obesity. He was a former smoker with a 25-pack 
year history. He had a history of bilateral high 
ligation and stripping of the great saphenous 
vein. Computed tomography (CT) of the chest 
revealed an irregular solid tumor measuring 
25 × 15 × 11 mm in the lower right lobe. The 
patient underwent right lower lobectomy and 
mediastinal lymphadenectomy by video-assist-
ed thoracoscopic surgery. The final histopatho-
logical diagnosis was predominantly papillary 
adenocarcinoma (G2, pT2aN0M0R0L1V0, clin-
ical stage IB) (IASLC/ITMIG, 8th edition). In the 
perioperative period, the patient received primary 
anticoagulant prophylaxis (40 mg enoxaparin 
administered subcutaneously once a day) and 
used compression stockings. He was readmitted 
2 weeks after discharge due to dry cough, fever, 
and radiological signs of a right pleural empyema. 
Pleural drainage was performed, and the patient 
received antibiotics and primary anticoagulant 
prophylaxis. Pleural fluid culture yielded Staphy-
lococcus aureus. The patient showed clinical and 
biochemical improvement and was discharged 
after 1 week of treatment. Follow-up chest CT 
scans and radiographs were recommended with 
no immediate need for adjunctive therapy. A sub-
sequent CT scan showed no evidence of recurrent 
or residual disease. Three months later, a CT scan 
showed sustained complete tumor regression, but 
CT pulmonary angiography revealed thrombosis 
in the right lower lobar pulmonary artery stump 
(Figure 1). The patient was asymptomatic. Trans-
thoracic echocardiography showed no signs of 
right ventricle overload or pulmonary hyperten-
sion. Doppler ultrasound of the lower extremities 
showed no evidence of venous thrombosis. The 
decision to introduce anticoagulants was made 
following a thorough risk-benefit analysis. The 
patient had PAST and persistent risk factors 
for venous thromboembolic disease including 
a history of lung cancer, congestive heart failure, 
obesity, varicose veins, arterial hypertension, and 
increased age. His bleeding risk was low. The 
patient received low-molecular-weight heparin 
(LMWH) (enoxaparin) at 1.5 mg/kg once daily for 
7 days and 1.0 mg/kg once daily for the following 
month. After 1 month, LMWH was switched to ri-
varoxaban at 20 mg once daily. After three months 
of anticoagulation, a follow-up CT pulmonary 
angiography revealed no pulmonary artery stump 
thrombosis (Figure 2). There were also no signs of 
cancer recurrence. Nonetheless, rivaroxaban was 
continued for 3 more months with no reported 
side effects and no observable signs of VTE or 
cancer recurrence in subsequent CT pulmonary 
angiographies. 
Discussion
Pulmonary artery stump thrombosis is a rare 
condition and its clinical significance is not ful-
ly understood. The risk factors for VTE, called 
Virchow’s triad (stasis of blood flow, endothelial 
Figure 1. Contrast-enhanced computed tomography of the chest 
showing right lower lobar pulmonary thrombosis (arrow)
Figure 2. Contrast-enhanced computed tomography of the chest fol-
lowing anticoagulation treatment
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injury, and hypercoagulability), are present after 
lung cancer surgeries and can promote pulmo-
nary arterial stump thrombosis formation. After 
being diagnosed with PAST, patients could ask 
their doctor about the possible complications and 
treatment options. For this reason, we conducted 
a literature review. 
In the largest retrospective analysis of 
648 surgeries for primary lung cancer, Moon et 
al. [4] demonstrated 25 cases (3.8%) of pulmonary 
arterial stump thrombosis. Another retrospective 
analysis of 473 lung cancer surgeries conducted 
by Lopez-Padilla et al. described 9 cases (1.8%) 
of PAST [5]. All the cases of PAST described by 
Moon et al. [4] and Lopez-Padilla et al. [5] were 
discovered incidentally on follow-up chest CT 
scans days or months after the surgery (median 
28 days, range 20–341 days; or 11.3 months, in-
terquartile range 2.7–42.2 months, respectively). 
These findings are in concordance with those 
done by other various authors who reported 
5 cases of PAST (only one of them was symp-
tomatic with the patient experiencing chest pain) 
detected in the period between 3 and 24 months 
after surgery [6–9]. However, there have also been 
6 case reports of late and very late arterial stump 
thrombosis detected up to 3–10 years after lung 
cancer surgery [9–14]. Interestingly, the later that 
the arterial stump thrombosis was discovered, the 
more frequently clinical symptoms were present. 
These symptoms included dyspnea, chest pain, 
and asthenia. The resulting sequelae were also 
more severe (e.g. acute PE with fatal outcome or 
chronic thromboembolic pulmonary hyperten-
sion with chronic progressive right heart failure) 
[10, 11, 13, 15]. 
The larger the surgery is, the greater the risk 
becomes for developing PAST. Pulmonary artery 
stump thrombosis in more frequently observed 
after pneumonectomy then lobectomy. Potential 
explanations for this include the longer arterial 
stump and greater activation of the coagulation 
cascade after major surgery [4, 6]. Different 
findings were observed about the localization of 
the PAST. Some authors noticed more frequent 
right-sided thrombi than left-sided ones [5–11, 
13]. Other authors observed the PAST more fre-
quently on the left side [4, 12, 14]. The stump on 
the left side is longer than the one on the right and 
can result in turbulent blood flow, but this the-
ory needs to be studied further. It is worthwhile 
to recommend that oncologic surgeons leave 
the arterial stumps as short as possible during 
pulmonary resections in order to decrease risk 
of the PAST. 
There is no consensus on how to treat pa-
tients with arterial stump thrombosis and wheth-
er they require any treatment at all. Most of the 
reported cases were discovered incidentally a few 
months after surgery during routine follow-up 
chest CT and had a benign outcome with total or 
partial thrombus regression [4–7, 9, 14]. None-
theless, it is worth emphasizing that in most of 
these cases, the patients received anticoagulants 
or antiplatelet agents [4, 5, 7–9, 11, 14–16]. The 
available reports do not clearly specify how treat-
ment decisions were made, with some reports 
containing only a retrospective cohort descrip-
tion. The decision about the treatment of PAST 
should be individual and based on concomitant 
diseases and the estimated risk of VTE progres-
sion and bleeding.
One of the suggested options is that the 
treatment of PAST should be the same as that of 
asymptomatic PE, but further studies are needed. 
According to the American Society of Clinical 
Oncology guidelines from 2019, patients with 
cancer and incidental PE should be managed in 
the same manner as those with symptomatic PE 
regardless of the extent of the disease (segmental 
or more proximal branches, multiple subsegmen-
tal vessels, or a single subsegmental vessel with 
proven concomitant deep vein thrombosis) [17]. 
Incidental PE has yielded similar clinical out-
comes when compared with those of symptomatic 
PE in cancer patients. Thus, it seems reasonable 
that regardless of whether it is isolated subseg-
mental PE or splanchnic or visceral vein thrombi 
diagnosed incidentally, the treatment should be 
implemented on a case-by-case basis and should 
consider the potential benefits and risks of antico-
agulation therapy [17]. As a result of clinical trials 
in recent decades, LMWH has been accepted as 
optimal anticoagulant therapy for thrombosis in 
cancer patients. Anticoagulation with LMWH is 
recommended over anticoagulation with vitamin 
K antagonists (VKAs) during the first 6 months of 
treatment [18]. Edoxaban or rivaroxaban should 
be considered as an alternative to LMWH in 
non-gastrointestinal cancer patients. Gastrointes-
tinal and genitourinary cancers carry an increased 
risk of major bleeding with the use of non-vita-
min-K antagonist oral anticoagulants (NOACs) 
[19, 20]. When NOACs are used, the risk of 
bleeding and drug interactions must be assessed 
[17]. The most recently published clinical trial 
on NOACs and VTE in cancer patients showed 
that apixaban was non-inferior to subcutaneous 
dalteparin for the treatment of cancer-associated 
VTE and did not carry an increased risk of major 
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bleeding. Thus, it can be used as an alternative to 
NOACs in VTE treatment in cancer patients [16]. 
The treatment options and regimens present-
ed in the available literature varied from case to 
case. Some authors administered anticoagulants 
with treatment modalities including: starting 
with LMWH followed by VKA [8, 10], starting 
with unfractionated heparin followed by VKA 
[11, 12, 14, 15], or using VKA alone [9] for at 
least 3 months or longer. Others administered no 
treatment at all [6]. Some used combinations of 
anticoagulants, antiplatelet drugs, or no treatment 
[4, 5]. The patients who were left untreated or 
received an antiplatelet agent alone were closely 
monitored and if the thrombus increased in size, 
an anticoagulant was usually initiated [4, 5]. Our 
patient had a history of lung cancer, pulmonary 
artery stump thrombosis, persisting risk factors 
for VTE (congestive heart failure, obesity, varicose 
veins, arterial hypertension, and increasing age), 
and a low risk of bleeding. After a discussion with 
the patient, we implemented anticoagulation with 
LMWH followed by rivaroxaban. We observed 
complete thrombus resolution, good treatment 
tolerance, and no side effects. The patient was 
closely monitored.
Most of the reported PAST cases had benign 
outcomes with complete regression or no progres-
sion for years [4, 5, 7, 14]. There are only a few 
reports indicating that arterial stump thrombosis 
may lead to thrombus size progression (n = 4) 
[4–6, 11], pulmonary embolism (n = 4) [10–13], 
or chronic thromboembolic pulmonary hyperten-
sion (n = 1) [10] with serious consequences. In 
conclusion, the presented case showed artery 
stump thrombosis that was discovered acciden-
tally during lung cancer surgery follow-up. To 
prevent VTE progression, empirical anticoagu-
lation was administered with a good outcome 
and no complications. This treatment option 
was decided based on an individual assessment 
of concomitant diseases and analysis of the risk 
of VTE progression and bleeding. Further studies 
are needed to address the question of whether or 
not patients with vascular stump thrombosis can 
benefit from anticoagulation therapy.
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